2014
Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study
Srihari VH, Tek C, Pollard J, Zimmet S, Keat J, Cahill JD, Kucukgoncu S, Walsh BC, Li F, Gueorguieva R, Levine N, Mesholam-Gately RI, Friedman-Yakoobian M, Seidman LJ, Keshavan MS, McGlashan TH, Woods SW. Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. BMC Psychiatry 2014, 14: 335. PMID: 25471062, PMCID: PMC4262386, DOI: 10.1186/s12888-014-0335-3.Peer-Reviewed Original ResearchConceptsEarly detectionEarly outcomesGeographic catchmentTIPS studyYounger patientsAppropriate patientsUntreated psychosisPsychosis onsetEffective treatmentCare providersPsychotic symptomsPublic education campaignsPsychotic disordersHelp-seeking behaviorSecondary aimComprehensive interventionPatientsIntervention servicesDUPEducation campaignsOutcomesSocial marketing approachPrimary aimTreatmentFES
2013
DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients
Shivarov V, Gueorguieva R, Stoimenov A, Tiu R. DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients. Leukemia Research 2013, 37: 1445-1450. PMID: 23962568, DOI: 10.1016/j.leukres.2013.07.032.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAML patientsEuropean Leukemia NetDNMT3A mutationsIndependent adverse prognostic factorPoor prognosis biomarkerAdverse prognostic factorSubgroup of patientsPotential prognostic valueHigh-risk genotypesRecurrent molecular aberrationsDNMT3A mutational statusShorter OSShorter RFSYounger patientsPrognostic factorsRisk stratificationWorse prognosisPrognostic valueAML subtypesMyeloid leukemiaPrognosis biomarkerPatientsMolecular aberrationsRisk genotypes